LeMaitre Vascular (NASDAQ:LMAT) Reaches New 12-Month Low Following Analyst Downgrade

Posted by Geri Gentry on Aug 7th, 2026

LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report)’s share price hit a new 52-week low on Thursday after Wells Fargo & Company lowered their price target on the stock from $104.00 to $94.00. Wells Fargo & Company currently has an equal weight rating on the stock. LeMaitre Vascular traded as low as $78.65 and last traded at $79.00, with a volume of 2183950 shares. The stock had previously closed at $105.78.

A number of other equities research analysts also recently weighed in on LMAT. Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Citizens Jmp increased their price target on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Weiss Ratings cut LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $110.60.

Read Our Latest Report on LMAT

More LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

Positive Sentiment: LeMaitre declared a quarterly dividend of $0.25 per share, payable September 3 to shareholders of record on August 20. The dividend represents an annualized yield of approximately 1.1%, providing some shareholder support. LeMaitre Vascular dividend announcement
Positive Sentiment: Despite missing estimates, second-quarter revenue increased 9.6% year over year to $70.38 million, while earnings per share rose from $0.60 to $0.74, indicating continued underlying business growth. LeMaitre Q2 earnings snapshot
Neutral Sentiment: Management will hold investor meetings at the Needham Virtual MedTech & Diagnostics 1×1 Conference on August 11. The event could provide updated business commentary, but no new financial information was announced. LeMaitre Needham conference announcement
Negative Sentiment: Second-quarter EPS of $0.74 missed the $0.81 consensus estimate, and revenue of $70.38 million came in below the $71.47 million forecast. The earnings shortfall has been the main reason for the recent selling pressure. LeMaitre misses Q2 estimates
Negative Sentiment: Barrington Research downgraded LMAT from “outperform” to “market perform,” while Wells Fargo lowered its price target from $104 to $94 and assigned an “equal weight” rating. The analyst actions reinforce concerns about near-term growth and valuation. LeMaitre analyst rating coverage
Negative Sentiment: The stock reached a new 12-month low following the downgrade activity, adding technical pressure to the fundamental concerns from the earnings miss. LeMaitre reaches 12-month low

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Annex Advisory Services LLC increased its stake in shares of LeMaitre Vascular by 6.0% in the 4th quarter. Annex Advisory Services LLC now owns 243,709 shares of the medical instruments supplier’s stock valued at $19,765,000 after purchasing an additional 13,692 shares during the last quarter. Kennedy Capital Management LLC raised its holdings in shares of LeMaitre Vascular by 14.8% during the 4th quarter. Kennedy Capital Management LLC now owns 247,907 shares of the medical instruments supplier’s stock worth $20,105,000 after buying an additional 32,040 shares in the last quarter. Wakefield Asset Management LLLP bought a new stake in shares of LeMaitre Vascular during the 4th quarter worth $1,130,000. Vanguard Group Inc. lifted its position in shares of LeMaitre Vascular by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock worth $131,547,000 after buying an additional 21,946 shares during the last quarter. Finally, Riverbridge Partners LLC acquired a new stake in LeMaitre Vascular in the first quarter valued at about $11,528,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Up 2.3%

The company has a quick ratio of 12.20, a current ratio of 16.31 and a debt-to-equity ratio of 0.40. The firm has a 50 day moving average of $96.80 and a two-hundred day moving average of $99.94. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of 28.36, a price-to-earnings-growth ratio of 2.28 and a beta of 0.53.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). The business had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The firm’s revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.60 EPS. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Thursday, August 20th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio is currently 35.09%.

About LeMaitre Vascular

(Get Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.